EDIT - Editas Medicine Inc
IEX Last Trade
3.75
0.040 1.067%
Share volume: 1,135,914
Last Updated: Fri 30 Aug 2024 09:59:56 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$3.71
0.04
1.08%
Fundamental analysis
12%
Profitability
0%
Dept financing
8%
Liquidity
75%
Performance
10%
Performance
5 Days
-3.36%
1 Month
-31.00%
3 Months
-27.66%
6 Months
-66.21%
1 Year
-58.63%
2 Year
-75.26%
Key data
Stock price
$3.75
DAY RANGE
N/A - N/A
52 WEEK RANGE
$3.62 - $11.69
52 WEEK CHANGE
-$0.59
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Cynthia Collins
Region: US
Website: http://www.editasmedicine.com/
Employees: 297
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://www.editasmedicine.com/
Employees: 297
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
unlocking the promise of genome editing to deliver life-changing medicines. editas medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.
Recent news